Patients can be diagnosed with metastatic disease at the time of their breast cancer diagnosis or after a period of time has elapsed since
their initial early breast cancer was treated.
Not exact matches
Initial results were announced from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with
early stage
breast cancer sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,
cancer sponsored by the National
Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,
Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN
Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,
Cancer Research Group (ECOG - ACRIN) with support from Genomic Health, Inc..
An
initial five - year, multicenter study of cryoablation to treat
early - stage
breast cancer sponsored by the National Cancer Institute found it to be 92 percent effective for complete ablation of invasive breast tumors smaller than 2 centimeters and 100 percent effective for complete ablation of invasive ductal breast cancer tumors smaller than 1 centi
cancer sponsored by the National
Cancer Institute found it to be 92 percent effective for complete ablation of invasive breast tumors smaller than 2 centimeters and 100 percent effective for complete ablation of invasive ductal breast cancer tumors smaller than 1 centi
Cancer Institute found it to be 92 percent effective for complete ablation of invasive
breast tumors smaller than 2 centimeters and 100 percent effective for complete ablation of invasive ductal
breast cancer tumors smaller than 1 centi
cancer tumors smaller than 1 centimeter.
11/19/2007 New Technology to Treat
Breast Cancer Shows Promise in
Early Application Physicians at the Rebecca and John Moores UCSD
Cancer Center will present the
initial outcomes of their use of a new device that delivers radiation therapy to a specific tumor site at the annual meeting of the Radiological Society of North America (R...